MYCN and neuroblastoma: In the neuroblastoma line SHEP, which harbors a MYCNER transgene, an unbiased pharmacological screen with 938 FDA‐approved drugs, recently demonstrated bortezomib, carfilzomib, cabazitaxel, pralatrexate, gemcitabine, vincristine, docetaxel, paclitaxel, etoposide, and doxorubicin to be the top ten MYCN‐associated pharmacological vulnerabilities [84].